ScinoPharm and CVie Therapeutics Limited to Jointly Develop New Heart Failure Drug
PRNewswire/ -- ScinoPharm Taiwan, Ltd (TWSE: 1789) and CVie Therapeutics Limited (CVie) jointly announced the initiation of a discovery and development collaboration to identify the new generation compound to Istaroxime, CVie's acute heart failure treatment currently in late Phase IIb trials in Italy and China. This collaboration marks the first time for ScinoPharm to collaborate with an external partner, CVie, from a discovery (pre-IND) perspective.
Virtual Colonoscopy Receives Highest Grade in the New U.S. Preventive Services Task Force Recommendation for Colorectal Cancer Screening
PRNewswire/ -- Bracco Diagnostics Inc. (BDI), the U.S. subsidiary of Bracco Imaging S.p.A., a global leading company in the diagnostic imaging business, announced today that The U.S. Preventative Services Task Force (USPSTF) issued a new recommendation to improve the rate of colorectal cancer screening (CRC). Computed tomography colonography (CTC), also known as Virtual Colonoscopy (VC), received an "A" rating as an alternative screening tool to colonoscopy in detecting colon cancer. The USPSTF recommendation was published in the June 21 online edition of the Journal of the American Medical Association. Bracco, a leader in CTC imaging innovation, has been providing two products that are essential components of CTC screenings since 2002.
Dräger Recalls VentStar Oxylog 3000 Pediatric Patient Breathing Circuit Due to Potential Valve Leakage
The VentStar Oxylog 3000 Pediatric Patient Breathing Circuit is being recalled because the firm discovered that the check valve on the circuit may leak. This could result in the patient re-breathing exhaled gas with reduced oxygen concentration and increased carbon dioxide levels. This can lead to serious health consequences, including excessive carbon dioxide in the bloodstream (hypercapnia) and increased acidity in the blood (acidosis), which could lead to death.
Ambry Genetics and Nationwide Collaborators Begin Prospective Multi-Site Study to Identify Hereditary Pancreatic Cancer
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (“Ambry”) and its collaborators at Beth Israel Deaconess Medical Center (Boston, MA), University of Pittsburgh (Pittsburgh, PA), and HonorHealth Research Institute (Scottsdale, AZ) today announce a prospective multi-site research study aimed to determine mutation prevalence, as well as psychological assessment and long-term follow up for treatment and care for pancreatic cancer patients with a hereditary predisposition to the disease. This study will gather valuable data for an underrepresented group of patients diagnosed with cancer carrying an extremely high mortality rate.
Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets
SEATTLE & NEW YORK & EMERYVILLE, Calif.--(BUSINESS WIRE)--Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Therapeutics, Inc. for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma. The binding domains were developed under a collaboration agreement between Eureka Therapeutics and MSK. The parties expect the BCMA CAR to enter human testing as early as 1H2017.
Multiple Myeloma Research Foundation (MMRF) and University of Michigan Team up on a New Molecular Profiling Initiative to Speed Genomic Sequencing Results to Patients
NORWALK, Conn. & ANN ARBOR, Mich.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF), together with the University of Michigan, today announced a collaboration to perform clinical-grade (CLIA) genomic sequencing on hundreds of relapsed and refractory multiple myeloma (MM) patients over a two year period. The purpose of the Molecular Profiling Initiative (MPI) is to provide timely CLIA genomic sequencing information to MM patients and their doctors, allowing them to make informed treatment decisions and identify potential treatment options based on a patient’s genomic alterations.
Caverion Delivers a Large Project for Novo Nordisk’s New Insulin Production Facility in Hillerød, Denmark
Caverion (HEX:CAV1V) delivers a Large Project for Novo Nordisk’s new insulin production facility in Hillerød, DenmarkCaverion has signed an agreement with global healthcare company, Novo Nordisk A/S on the delivery of a Large Project for a new pharmaceutical filling factory in Hillerød, Denmark. Caverion is responsible for Project Execution within the discipline of Ventilation. The contract has a volume of approximately EUR 5.4 million. For more information www.caverion.fi/Csaga
PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Gedeon Richter Plc., today provided a clinical and regulatory update on cariprazine. For more than a decade both companies have conducted over 20 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine for patients suffering from a broad range of mental health illnesses.